In Q1 FY2026 (ended March 31, 2026), CapsoVision reported revenue of $2.79 million, up 32.3% year-over-year. Net loss widened to $7.03 million from $5.38 million a year ago, with diluted EPS of -$0.15. Operating loss was $7.09 million, and stockholders' equity stood at $20.22 million.
•Revenue increased 32.3% YoY to $2.79 million.
•Net loss was $7.03 million, compared to a loss of $5.38 million in Q1 FY2025.
•Diluted EPS was -$0.15, versus -$0.08 in the prior year quarter.
•Stockholders' equity was $20.22 million as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
CapsoVision, Inc., a medical technology company manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon)
CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution. Its portfolio also includes CapsoView, a data access reading device for viewing capsule videos, CapsoAccess, a Capsule data access system, and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals.
Products are distributed to distributor customers who resell products. Incorporated in 2005 and headquartered in Saratoga, California, CapsoVision was formerly known as Capso Vision Inc. before rebranding in May 2016.
CapsoVision, Inc. is a medical technology company that manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. Its main product is the CapsoCam Plus, a capsule endoscopy system used for visualization of the small bowel mucosa in adults and children aged 2 years and above. The company also offers CapsoCam Colon for visualization of the colon and detection and measurement of polyps. Additionally, CapsoVision is developing CapsoColon 3D for large intestines (colon). The company provides a cloud-based software-as-a-service ecosystem called CapsoCloud for off-premises video access and download. Other products include CapsoView, a data access reading device; CapsoAccess, a capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand. CapsoVision also offers capsule video reading services.
On which stock exchange is CapsoVision (CV) listed and what currency is used?
CapsoVision, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CV. The trading currency for its shares is the US Dollar (USD). As a company headquartered in the United States, its stock is traded in the US market, providing investors with exposure to the medical devices industry within the healthcare sector.
What sector and industry does CapsoVision (CV) operate in?
CapsoVision, Inc. operates in the Healthcare sector and specifically within the Medical Devices industry. The company focuses on developing and marketing endoscopic video imaging devices for gastrointestinal imaging. Its products are used by healthcare providers such as gastrointestinal medical practices, clinics, and hospitals to diagnose and monitor conditions affecting the small bowel and colon. As a medical device company, CapsoVision's innovations aim to improve visualization and detection of abnormalities in the digestive system.
Where is CapsoVision (CV) headquartered and what markets does it serve?
CapsoVision, Inc. is headquartered in Saratoga, California, United States. The company was incorporated in 2005 and was formerly known as Capso Vision Inc. before rebranding in May 2016. CapsoVision serves gastrointestinal medical practices, clinics, and hospitals. Its products are distributed to distributor customers who resell the products, indicating a B2B distribution model. While the headquarters is in the US, the company's products are likely available in various markets through its distributor network, though specific geographic markets are not detailed in the provided data.
How does CapsoVision (CV) make money?
CapsoVision generates revenue primarily through the sale of its endoscopic video imaging devices and related systems. The company's product portfolio includes the CapsoCam Plus capsule endoscopy system, CapsoCam Colon, and the upcoming CapsoColon 3D. Additionally, it offers CapsoCloud, a cloud-based software-as-a-service platform for video access and download, which likely involves subscription or usage fees. CapsoVision also sells accessory products such as CapsoView (reading device), CapsoAccess (data access system), and CapsoRetrieve (retrieval kit). Furthermore, the company provides capsule video reading services, which may generate service revenue. Products are sold through distributors who resell to end customers, so revenue comes from wholesale sales to distributors.